CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

BMS’ neuro renaissance was built on back of Celgene mega-merger

Positive
AI Analysis

Summary

Bristol Myers Squibb is leveraging its Celgene acquisition to expand its neurology and psychiatry portfolio while also being rumored for a potential mega-merger with AstraZeneca. The company is pursuing a continuum of care approach across its therapeutic areas.

Importance:5/10
Sentiment:
0.30
oncologyneurologypsychiatryM&Apipeline expansion
Related Companies

Read the original article

Published by BioSpace on August 31, 2026 5:01 AM

Read Original